<DOC>
	<DOCNO>NCT03069911</DOCNO>
	<brief_summary>This study evaluate efficacy onabotulinumtoxinA ( BOTOXÂ® ) treatment depression associate Idiopathic Parkinson Disease adult . As Randomized Controlled Trial , half participant receive onabotulinumtoxinA injection half receive placebo saline solution .</brief_summary>
	<brief_title>Randomized Controlled Trial OnabotulinumtoxinA Depression Parkinson Disease</brief_title>
	<detailed_description>Depression common , treatable , comorbid condition often see person Idiopathic Parkinson Disease ( iPD ) . Depression Parkinson Disease may hard treat patient iPD may sensitive side effect medication . As result , treatment well side effect profile antidepressant may equivalent ( good ) option . OnabotulinumtoxinA purify formulation botulinum toxin serotype A widely utilized neurological ( cosmetic ) purpose medicine . OnabotulinumtoxinA preliminary study show may beneficial treatment Major Depressive Disorder give isolated injection facial muscle ( corrugator procerus ) . When give low dos , onabotulinumtoxinA think minimal side effect . The investigator propose single treatment onabotulinumtoxinA may improve symptom depression person Parkinson Disease three month compare placebo . The investigator plan use subjective objective evaluation depression symptom regular physical exam ensure physical ( motor ) symptoms Parkinson Disease worsen .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Written inform consent obtain English language ; They 18 95 year old ; They meet United Kingdom Brain Bank Criteria probable idiopathic Parkinson disease ; They meet Diagnostic Statistical Manual ( DSM ) IV criterion major depressive disorder ( MDD ) diagnose M.I.N.I . screen ; They judge investigator capacity understand nature study ; They willing comply requirement study ; They consider investigator likely adhere protocol . They treat onabotulinumtoxinA inject facial muscle reason 3 month prior screen ; They Bipolar Disorder , PostTraumatic Stress Disorder , Psychotic Disorder nonunipolar depressive disorder principal diagnosis 6 month prior screen ; They endorse active suicidal ideation enrollment study visit , attempt suicide six month prior screen ; They history substance abuse dependence 2 month prior screen ; They test positive illicit drug urine screen , adequately explain satisfaction investigator They consider significant risk commit homicide ; They unstable medical condition ; Women childbearing potential pregnant consider become pregnant length study ; There change PD medication psychotherapy treatment regimen 30 day precede screening ; They regard , reason , principal investigator unsuitable candidate protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>Parkinsonism</keyword>
	<keyword>Depression</keyword>
	<keyword>OnabotulinumtoxinA</keyword>
	<keyword>BOTOX</keyword>
</DOC>